Eisai seizure drug spurs 5% weight loss

Could Eisai have an obesity drug just waiting to step onstage? The Japanese drugmaker's epilepsy treatment Zonegran helped patients lose weight--at least as much weight as patients in Arena Pharmaceuticals' ($ARNA) trial of its recently approved Belviq. As Bloomberg reports, study patients who took 400 mg of Zonegran daily for a year lost 7.3 kg on average, significantly more than the 4 kg placebo patients shed. Story

 

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.